High-Purity Cannabidiol for Refractory Rett Syndrome Seizures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments, including anti-epileptic drugs (AEDs), fail to provide seizure freedom for 30% of epilepsy patients, particularly those with treatment-resistant epilepsy syndromes like Rett syndrome, leading to neurological damage in children and young adults.
Innovation Solution
The use of highly purified cannabidiol (CBD), with a concentration of greater than 95% and minimal tetrahydrocannabinol (THC), administered alone or in combination with AEDs, to treat seizures associated with Rett syndrome, including tonic, absence, and focal seizures with impairment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-epileptic drugs (AEDs) are used to treat seizures, then seizure control is achieved in 70% of patients, but 30% of patients with treatment-resistant epilepsy continue to experience seizures and neurological damage
Solution Approach 1:
The patent introduces a new chemical compound (cannabidiol/CBD) with different pharmacological properties compared to existing AEDs. By changing the chemical parameter (using a cannabinoid compound instead of conventional AEDs), the treatment achieves efficacy in previously treatment-resistant cases of Dravet syndrome and Lennox-Gastaut syndrome, as well as Rett syndrome seizures
Solution Approach 2:
The patent utilizes highly purified cannabidiol (≥95% purity) as a composite pharmaceutical formulation. This purified CBD preparation, with controlled minimal THC content (≤0.15%), represents a refined composite material that delivers consistent therapeutic effects while minimizing adverse effects from other cannabis constituents
2Reliability
If highly purified CBD is administered to treat Rett syndrome seizures, then significant seizure reduction is achieved (up to 100% reduction in focal seizures), but the treatment requires high purity standards and controlled THC levels
Solution Approach 1:
The patent applies extraction and purification processes to isolate cannabidiol from the cannabis plant material. Through systematic removal of impurities and other cannabinoids, the formulation achieves ≥95% CBD purity with minimal THC (≤0.15%), concentrating the therapeutic component while eliminating unwanted constituents
Solution Approach 2:
The patent implements different quality specifications for different components: high concentration of CBD (≥95%) for therapeutic efficacy, and strictly limited concentrations of other cannabinoids (THC ≤0.15%, CBDV ≤1.0%, CBD-C4 ≤0.5%, CBD-C1 ≤0.15%). This localized quality control ensures optimal therapeutic effect while minimizing adverse effects
3Reliability
If CBD is administered at higher doses to achieve greater seizure control, then seizure frequency reduces significantly, but the risk of adverse effects may increase
Solution Approach 1:
The patent converts the potential harm of THC (psychoactive effects and adverse reactions) into a benefit by strictly limiting its content to ≤0.15% in the formulation. This minimal THC level is sufficient to provide therapeutic anti-seizure effects while avoiding the harmful psychoactive effects associated with higher THC concentrations
Solution Approach 2:
The patent uses a partial action approach by administering CBD at controlled doses (starting at 5-10 mg/kg/day and titrating up to maximum 50 mg/kg/day) rather than maximal doses. This gradual titration achieves therapeutic seizure control while minimizing the risk of dose-related adverse effects
Data Source
AI summary
The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with Rett syndrome. In a further embodiment the types of seizures include tonic, tonic- clonic, absence seizures and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.